On April 17, 2026, Third Rock Ventures V, L.P. sold 426,005 shares of Rapport Therapeutics, Inc. (RAPP) in an open-market transaction valued at approximately $17.18 million, representing 5.3% of its total holdings. This sale, executed under a Rule 10b5-1 trading plan, indicates a pre-planned liquidity event rather than a reaction to market conditions. Following the transaction, Third Rock retains a significant stake of 6,709,228 shares, suggesting continued confidence in the company’s prospects.
The timing of the sale is noteworthy, occurring after Rapport Therapeutics’ stock surged 230% over the past year. This strong performance aligns with the company’s promising clinical results for its lead candidate, RAP-219, which demonstrated a 90% median reduction in clinical seizures in recent trials. The ongoing development of additional pipeline candidates and the initiation of Phase 3 trials in the near term could serve as catalysts for future growth.
For investors, Third Rock’s strategic trimming of its position may reflect a prudent approach to profit-taking while maintaining substantial exposure to Rapport’s potential. Monitoring the outcomes of upcoming trials will be crucial for assessing the company’s trajectory and investment viability.
Source: fool.com